等待开盘 11-06 09:30:00 美东时间
+0.230
+2.07%
Companies Reporting Before The Bell • Avient (NYSE:AVNT) is estimated to report...
11-05 19:12
Enovix (NASDAQ:ENVX) is gearing up to announce its quarterly earnings on Wednes...
11-05 02:02
Here's a look at the most heavily shorted stocks in the market as investors look for the next Beyond Meat.
10-23 01:42
Enovix Corporation, a leader in advanced silicon battery technology, will release its third-quarter financial results on November 5, 2025, followed by a live video call at 2:00 PM PT / 5:00 PM ET to discuss business updates, milestones, and financial results. Investors can register via the provided link and submit questions in advance. Enovix is known for its high-energy-density lithium-ion batteries and operates globally with facilities in India...
10-21 21:07
Enovix Corporation has been named to Fast Company's Next Big Things in Tech list for its advanced silicon battery technology, which is set to redefine industry standards. The company’s AI-1™ batteries offer the highest energy density, enhancing performance for smartphones, AI devices, wearables, and electric vehicles. Enovix is preparing to scale production in 2026 through facilities in Malaysia and South Korea.
10-15 20:01
Enovix Corp's (NYSE:ENVX) short interest as a percent of float has risen 6.67% ...
10-11 03:00
Enovix Korea received the 2025 Best Workplaces of Korea for Job Creation award from the Ministry of Employment and Labor, recognizing its exceptional employee-focused policies, such as profit-sharing, stock purchase plans, transparent communication, and innovative rewards. With only 100 companies honored nationwide, this prestigious award highlights Enovix's commitment to fostering a workplace culture that prioritizes employee engagement, satisfa...
09-12 21:27
Enovix shares are trading lower Thursday after the company announced a $300 million convertible notes offering.
09-12 00:14
Enlivex Therapeutics Ltd. reported promising Phase IIa results for Allocetra™ in knee osteoarthritis (KOA), showing significant pain reduction and functional improvement in older patients. The treatment was well-tolerated, with no serious adverse events. Key findings included a 72% reduction in pain and 109% improvement in function compared to placebo. Enlivex plans to release six-month data by November 2025 and initiate a Phase IIb trial in Q2 2...
09-11 12:00